Ardelyx Reinforces Long-Term Safety of XPHOZAH in Dialysis Patients

Event summary

  • Ardelyx presented data at NKF’s Spring Clinical Meetings on May 7, 2026, supporting the long-term safety of XPHOZAH in chronic kidney disease patients on dialysis.
  • Analysis from NORMALIZE (18-month extension) and OPTIMIZE (26-week) trials showed no clinically meaningful changes in serum electrolytes other than phosphate reduction.
  • XPHOZAH is the only FDA-approved phosphate absorption inhibitor for dialysis patients with inadequate response to phosphate binders.
  • Ardelyx is sponsoring a Peer Exchange on May 8 to discuss hyperphosphatemia treatment and side effect management.

The big picture

Ardelyx’s presentation underscores the growing importance of targeted therapies for chronic kidney disease, particularly as the dialysis patient population expands. The long-term safety data for XPHOZAH could position it as a key player in a market dominated by phosphate binders, potentially reshaping treatment paradigms for hyperphosphatemia. The company’s focus on optimizing phosphate management aligns with broader industry trends toward precision medicine in nephrology.

What we're watching

Market Adoption
Whether XPHOZAH can gain broader acceptance as a first-line treatment for hyperphosphatemia in dialysis patients.
Competitive Positioning
How Ardelyx differentiates XPHOZAH from existing phosphate binders in terms of efficacy and safety.
Regulatory Expansion
The pace at which Ardelyx pursues additional indications or approvals for XPHOZAH beyond its current use case.